Certara (CERT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.08
- Estimate
- $0.09
- Surprise
- -12.2%
- Revenue (period 2026-06-30)
- $93.3M
- Score at report (before → after)
- 4.7 → 4.8/10
Revenue source: xbrl.
How the report landed
Certara (CERT) reported diluted EPS of $0.08, in line with the $0.09 estimate. TrendMatrix's engine moved from Hold (4.7/10) to Sell at 4.8/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates CERT Sell at 4.5/10.
1 of the last 4 quarters beat the estimate; this quarter's -12.2% surprise compares with a -2.3% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Positive insider activity
What argues against it
- Analyst target reached - limited upside remaining
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.4)
- Consecutive earnings misses (2)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $7.90
- Price target
- $8.70
- Stop
- $7.62
- Upside to target
- +10.1%
Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.
CERT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Health Information Services
- Market cap
- $1.24B
- P/E (fwd)
- 20.8
- 52-week range
- $4.45–$13.88
- Off 52-week high
- 43.1%
- RSI (14)
- 49
- Volume vs avg
- 0.54×
- Score today
- 4.5/10